Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
Recruiting
Observational Study
RSV
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 4
- Sex
- Any
- Study type
- Observational
- Participants needed
- 160,000 (estimated)
- Sponsor
- Instituto Sistemas Complejos de Ingeniería · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The primary aim is to determine the effectiveness of the monoclonal antibody nirsevimab in preventing RSV infection in infants based on the integrated analysis of several national databases before, during, a…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Subjects born between October 1st, 2023, to September 31st, 2024.
* Subjects born with 29 weeks of gestational age (wga) or less who were born between July 1st, 2023 and October 1st, 2023
* Subjects born with Bronchopulmonary Dysplasia (BPD), 32 or less wga and/or a birth weig…
Contacts